Guest Editorial PAMN: How cancer centers develop ways to communicate the value of research December 09, 2022Vol.48 No.44By Heidi Findlay
FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC December 02, 2022Vol.48 No.43By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
Conversation with The Cancer Letter Roy Herbst: I hope Pragmatica-Lung will become the norm December 02, 2022Vol.48 No.43By Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Ellen Sigal: Pragmatica-Lung may be a model for other trials that are unnecessarily complex December 02, 2022Vol.48 No.43By Matthew Bin Han Ong
Guest Editorial A “new normal” for NCI-sponsored clinical trials is long overdue November 18, 2022Vol.48 No.42By Richard L. Schilsky
A brief report sets forth a “new normal,” lets NCI start to streamline clinical trials November 11, 2022Vol.48 No.41By Paul Goldberg
Conversation with The Cancer Letter NCI’s Doroshow: “These recommendations are something that we can implement right away” November 11, 2022Vol.48 No.41By Paul Goldberg
NCI Bertagnolli sets out eight “core principles” for NCI: “We’ve got to be nimbler, faster” November 11, 2022Vol.48 No.41
In Brief Gregory Reaman named scientific director of NCI’s Childhood Cancer Data Initiative November 11, 2022Vol.48 No.41
Conversation with The Cancer Letter Children’s National and UCL team receives $25M Grand Challenges award to study CAR T in pediatric solid tumors November 04, 2022Vol.48 No.40By Jacquelyn Cobb
